PT - JOURNAL ARTICLE AU - Laing, Eric D. AU - Sterling, Spencer L. AU - Richard, Stephanie A. AU - Phogat, Shreshta AU - Samuels, Emily C. AU - Epsi, Nusrat J. AU - Yan, Lianying AU - Moreno, Nicole AU - Coles, Christian AU - Mehalko, Jennifer AU - Drew, Matthew AU - English, Caroline AU - Chung, Kevin K. AU - Clifton, G. Travis AU - Munster, Vincent J. AU - de Wit, Emmie AU - Tribble, David AU - Agan, Brian K. AU - Esposito, Dominic AU - Lanteri, Charlotte AU - Mitre, Edward AU - Burgess, Timothy H. AU - Broder, Christopher C. TI - A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and controls for pre-existing seasonal human coronavirus antibody cross-reactivity AID - 10.1101/2020.10.14.20207050 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.14.20207050 4099 - http://medrxiv.org/content/early/2020/10/16/2020.10.14.20207050.short 4100 - http://medrxiv.org/content/early/2020/10/16/2020.10.14.20207050.full AB - With growing concern of persistent or multiple waves of SARS-CoV-2 in the United States, sensitive and specific SARS-CoV-2 antibody assays remain critical for community and hospital-based SARS-CoV-2 surveillance. Here, we describe the development and application of a multiplex microsphere-based immunoassay (MMIA) for COVD-19 antibody studies, utilizing serum samples from non-human primate SARS-CoV-2 infection models, an archived human sera bank and subjects enrolled at five U.S. military hospitals. The MMIA incorporates prefusion stabilized spike glycoprotein trimers of SARS-CoV-2, SARS-CoV-1, MERS-CoV, and the seasonal human coronaviruses HCoV-HKU1 and HCoV-OC43, into a multiplexing system that enables simultaneous measurement of off-target pre-existing cross-reactive antibodies. We report the sensitivity and specificity performances for this assay strategy at 98% sensitivity and 100% specificity for subject samples collected as early as 10 days after the onset of symptoms. In archival sera collected prior to 2019 and serum samples from subjects PCR negative for SARS-CoV-2, we detected seroprevalence of 72% and 98% for HCoV-HKU1 and HCoV-0C43, respectively. Requiring only 1.25 µL of sera, this approach permitted the simultaneous identification of SARS-CoV-2 seroconversion and polyclonal SARS-CoV-2 IgG antibody responses to SARS-CoV-1 and MERS-CoV, further demonstrating the presence of conserved epitopes in the spike glycoprotein of zoonotic betacoronaviruses. Application of this serology assay in observational studies with serum samples collected from subjects before and after SARS-CoV-2 infection will permit an investigation of the influences of HCoV-induced antibodies on COVID-19 clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has been funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072 and the Defense Health Program, U.S. DoD, under award HU0001190002. This project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E. VJM and EdW are supported by the Intramural Research Program of the National Institutes of Allergy and Infectious Diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:These research protocols, IDCRP-085, IDCRP-045 and COVID-19 NYC, were approved by the USU IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocols and datasets used and/or analyzed during the current study are available from the corresponding author(s) on reasonable request.